MARKET RADAR
SENSEX     NIFTY      Refresh
YOU ARE HERE >  Moneycontrol >  Markets > Announcements >  Pharmaceuticals > Announcement - Alembic Pharma
Alembic Pharma
BSE: 533573NSE: APLLTDISIN: INE901L01018

15th-Jun-2012 12:56Source: BSE

Alembic Pharma - Settlement of Paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon® by Novartis

Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated June 15, 2012, titled "Settlement of Paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon® by Novartis".

More Announcements on:

23rd-May-2013 17:42Source: BSE

Alembic Pharma - Auditors Report for March 31, 2013

3rd-May-2013 09:18Source: NSE

Alembic Pharmaceuticals Limited

2nd-May-2013 17:02Source: BSE

Alembic Pharma - Board recommends Dividend

2nd-May-2013 16:23Source: NSE

Alembic Pharmaceuticals Limited

2nd-May-2013 16:22Source: NSE

Alembic Pharmaceuticals Limited

2nd-May-2013 15:24Source: NSE

Alembic Pharmaceuticals Limited

19th-Mar-2013 18:11Source: BSE

Alembic Pharma - Board to consider Dividend

5th-Mar-2013 13:35Source: NSE

Alembic Pharmaceuticals Limited

5th-Mar-2013 11:53Source: BSE

Alembic Pharma - Alembic Receives USFDA Approval for its NDA - Desvenlafaxine Base Extended Release Tablets

21st-Jan-2013 15:48Source: NSE

Alembic Pharmaceuticals Limited

1 2 3 4 5 Next >>
Add to Watchist
close[x]
Have you invested in these stocks? You can track them better in your Portfolio
Edit Watchlist
Thursday`s damage may keep mkt edgy for next few days: Udayan Mukherjee. Do you agree?
Yes
No

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window